Investing.com - Can Fite Biopharma ADR reported on Friday third quarter earnings that beat analysts' forecasts and revenue that topped expectations.
Can Fite Biopharma ADR announced earnings per share of $-0.010 on revenue of $613K. Analysts polled by Investing.com anticipated EPS of $-0.090 on revenue of $300K.
Can Fite Biopharma ADR shares are down 33.72% from the beginning of the year and are trading at $0.855 , down-from-52-week-high.
Can Fite Biopharma ADR follows other major Healthcare sector earnings this month
Can Fite Biopharma ADR's report follows an earnings beat by Eli Lilly on Tuesday, November 1, 2022, who reported EPS of $1.98 on revenue of $6.94B, compared to forecasts EPS of $1.91 on revenue of $6.91B.
AbbVie had beat expectations on Friday, October 28, 2022 with third quarter EPS of $3.66 on revenue of $14.81B, compared to forecast for EPS of $3.58 on revenue of $14.93B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar